What is Molecular Partners?
Molecular Partners AG is a specialized clinical-stage biotech enterprise focused on the development of DARPin therapeutics. These custom-built protein drugs represent a novel class of medicine designed to overcome the limitations of existing treatment paradigms. By leveraging a modular design, the company is actively addressing critical unmet needs across ophthalmology, oncology, and infectious disease. Through strategic alliances with global pharmaceutical leaders, Molecular Partners has successfully transitioned its pipeline from preclinical research into advanced clinical development, establishing a robust footprint in the high-growth protein engineering market.
How much funding has Molecular Partners raised?
Molecular Partners has raised a total of $199.3M across 4 funding rounds:
Series A
$15.6M
Series B
$44.2M
Stock Offering
$108.3M
Share Placement
$31.2M
Series A (2007): $15.6M with participation from Index Ventures, Endeavour Vision, and BB Biotech Ventures
Series B (2009): $44.2M led by Index Ventures, Endeavour Vision, Essex Woodlands, and BB Biotech Ventures
Stock Issuance/Offering (2014): $108.3M, investors not publicly disclosed
Share Placement (2016): $31.2M, investors not publicly disclosed
Key Investors in Molecular Partners
Index Ventures
A venture firm investing in the next generation of entrepreneurs from seed to IPO, partnering with founders who challenge the status quo to build enduring companies.
Endeavour Vision
A leading investment advisory firm specializing in transformative healthcare technologies, providing strategic support in commercial strategy, clinical trials, and regulatory submissions.
BB Biotech Ventures
A healthcare-dedicated venture capital firm that invests in private companies developing and marketing drugs and medical devices, leveraging deep sector knowledge for value creation.
What's next for Molecular Partners?
With the recent capital injection, Molecular Partners is well-positioned to accelerate its clinical development programs and expand its therapeutic reach. The company's strategic roadmap emphasizes the maturation of its DARPin pipeline, aiming to translate its unique protein engineering capabilities into tangible patient outcomes. As the firm continues to navigate the complexities of late-stage clinical trials, the focus remains on scaling its internal R&D infrastructure and deepening its collaborative partnerships. This financial backing provides the necessary runway to sustain long-term innovation, ensuring that the company remains at the forefront of the evolving biopharmaceutical landscape while driving value for stakeholders through scientific excellence and clinical validation.
See full Molecular Partners company page
